Oligodendrogliomas lacking 1p19q co-deletion exhibit sensitivity to chemotherapy but are predisposed to recurrence, suggesting that CD58-targeted therapy could potentially delay disease recurrence. Here, CD58 is linked to oligodendroglioma.